Loading…
← CockpitCompetitor Analysis › 600812.SS North China Pharmaceutical Company Ltd. Class AOpen in the cockpit ↗

North China Pharmaceutical Company Ltd. Class A600812.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

State-owned Hebei antibiotics pioneer, one of China's oldest large-scale penicillin and API manufacturers.

≈ A Chinese state-owned Pfizer-generics ancestorMomentum strong 60
Mkt cap
$1.08B
US dollars, full cap
Free float
67%
of shares outstanding
$/day
$41.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-0.2 pp
WACC 5.0%
Hurdle
+5 pp
Req g minus delivered
Close · CNYCN¥4.46
1D-0.9%
1W-7.1%
1M-19.1%
3M-12.2%
6M-11.7%
YTD-19.4%
1Y-27.4%
ATR %4.7%
52w lowhigh35.4% off high

What North China Pharmaceutical does

State-owned Hebei antibiotics pioneer, one of China's oldest large-scale penicillin and API manufacturers.

Sells antibiotic active ingredients such as penicillin by the tonne to generic drugmakers worldwide, and finished drugs to hospitals, so earnings follow the global price of a commodity-like ingredient and the cost of grain-based fermentation inputs. A Hebei state-owned group controls it.

In one line: A Chinese state-owned Pfizer-generics ancestor.

Products and services

  • Penicillin and antibiotic APIs
  • Finished antibiotic formulations
  • Amino acids and biochemicals

Customers

  • Hospitals
  • Generic-drug formulators worldwide

Where it sits in the supply chain

  • Pharmaceuticals
  • Active ingredients
  • Antibiotics and APIs

What could go right

  • Global antibiotic API demand

What could go wrong

  • Overcapacity and price competition
  • Environmental compliance costs

Moat: none (scale). Legacy state-owned scale in commodity antibiotics, but limited pricing power against newer low-cost rivals.

Headquarters: Shijiazhuang, Hebei, China · Founded: 1953 · Employees: 9,972

Named competitors

North China Pharmaceutical at a glance

Size North China Pharmaceutical (600812.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.08B, the 2003rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.46 on 18 Nov 2026.

Performance Over six months the shares fell 11.7%, against -7.1% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 20 in its peer set.

Growth Revenue fell 20.7% over the last twelve months (peer median -1.2%); the operating margin is 5.4% (peer median 8.9%).

Valuation It trades at 2.4× enterprise value to sales against a peer median of 3.0× (8th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.2 points below its cost of capital (5.0% WACC).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 93600812.SS 90
Six months, rebased to 100: North China Pharmaceutical against the median of its 20 peers (local-currency closes).

North China Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥7.77BCN¥9.20BCN¥9.83BCN¥10.1BCN¥10.5B
Revenue growth—-6%-2%-4%—
Gross profitCN¥2.77BCN¥2.55BCN¥2.91BCN¥3.05BCN¥3.33B
EBITDAn/aCN¥1.58BCN¥1.55BCN¥1.43BCN¥691M
Net incomeCN¥89.4MCN¥183MCN¥127MCN¥4.89M-CN¥689M
Free cash flowCN¥697MCN¥695MCN¥446MCN¥402MCN¥456M
Capital expenditureCN¥539MCN¥542MCN¥784MCN¥623MCN¥550M
Total debtCN¥11.6BCN¥11.7BCN¥11.9BCN¥11.7BCN¥11.9B

Quarterly statements and history in the cockpit →

North China Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%OMERMEDCLPYCVETO300119237690VIYASH1952006280BLUEJET600789BSLNCMHC0027374547688513600812.SS6-month return →1-month return →
Up and to the right = strong over both horizons. North China Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×20×40×MEDCLVETO300119237690VIYASH1952BLUEJETCMHC002737002550600812.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. North China Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%VETO300119237690VIYASHBLUEJET600789BSLN0027370025504553600812.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. North China Pharmaceutical is the large dot.

North China Pharmaceutical competitors and peer comparison

Head to head with its named competitors (600812.SS vs 600789.SS vs 000597.SZ vs 600664.SS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
North China Pharmaceutical 600812.SS$1.08B-12%-21%5%2.4×1.0%
Shandong Lukang Pharmaceutical 600789.SS$1.05B-18%-7%3%1.5×2.5%
Northeast Pharmaceutical 000597.SZ$895M-14%-6%3%0.9×-7.6%
Harbin Pharmaceutical 600664.SS$1.78B+32%+2%5%0.7×-5.3%

How North China Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

North China Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure600812.SSPeer medianRank in peer set
1-month return-19.1%-1.1%3rd lowest of 21
6-month return-11.7%-7.1%7th lowest of 20
Distance from 52-week high-35.4%-26.8%7th lowest of 21
Revenue growth (TTM)-20.7%-1.2%3rd lowest of 17
Operating margin5.4%8.9%8th lowest of 18
EV / Sales2.4×3.0×8th cheapest of 18
Growth the price implies (Req g, 7 yrs)1.0%3.4%5th least demanding of 12
Growth delivered (Del g)-4.2%+11.3%2nd lowest of 12
Hurdle (Req g minus delivered)+5.2 pp-4.0 pp3rd most demanding of 12
ROIC minus cost of capital-0.2 pp-1.5 pp9th highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
North China Pharmaceutical 600812.SSChina$1.08B-12%-21%5%2.4×1.0%-4.2%
Omeros OMERUnited States$1.08B+24%n/a-56%17.3×n/an/a
MedinCell MEDCL.PAFrance$1.09B+4%-23%-131%49.6×n/an/a
PYC Therapeutics PYC.AXAustralia$1.09B+29%n/an/an/an/an/a
Vetoquinol VETO.PAFrance$1.10B+19%-1%15%1.5×-3.6%+4.2%
Tianjin Ringpu Bio-technology 300119.SZChina$1.11B-7%-9%11%2.3×4.9%+11.3%
ST Pharm 237690.KSSouth Korea$1.11B-51%+26%18%3.5×4.2%+21.7%
Viyash Scientific VIYASH.NSIndia$1.11B+3%+124%13%2.9×36.3%+20.4%
Symbiotec Pharmalab SYMBIOTEC.NSIndia$1.12Bn/an/an/an/an/an/a
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%3.0×n/an/a
GC Biopharma 006280.KSSouth Korea$1.12B-10%-3%4%1.2×n/an/a
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%8.1×40.8%+13.8%
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%1.5×2.5%+6.5%
Basilea Pharmaceutica BSLN.SWSwitzerland$1.04B+33%+5%24%3.2×-5.6%+12.7%
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
Cosmo CMHC.SWSwitzerland$1.13B-30%-45%-13%8.2×n/an/a
Sunflower Pharmaceutical 002737.SZChina$1.04B-11%+31%-7%1.7×-6.5%-7.7%
Changzhou Qianhong Bio-Pharma 002550.SZChina$1.14B-12%-2%15%4.2×3.4%-1.2%
Towa Pharmaceutical 4553.TJapan$1.03B-10%+7%9%1.2×-0.3%+12.1%
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%1.4×n/an/a
Chengdu Easton Biopharmaceuticals 688513.SSChina$1.03B-33%-2%13%4.2×4.4%+7.7%

Questions

Who are North China Pharmaceutical's main competitors?
Named competitors: Shandong Lukang Pharmaceutical (600789.SS), Northeast Pharmaceutical Group (000597.SZ), Harbin Pharmaceutical Group (600664.SS). The cockpit's measured peer set (industry) also includes Omeros (OMER), MedinCell (MEDCL.PA), PYC Therapeutics (PYC.AX), Vetoquinol (VETO.PA), Tianjin Ringpu Bio-technology (300119.SZ), ST Pharm (237690.KS).
Is North China Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 2.4× against a peer median of 3.0×, 8th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has North China Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -11.7% against -7.1% for the median peer; over one year -27.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.